Viatris Inc (VTRS) Defeats Biogen's (BIIB) Attempt to Revive Tecfidera Patent

Viatris Inc. (NASDAQ: VTRS) today announced that it is pleased with the decision by the United States Court of Appeals for the Federal Circuit denying Biogen's request that the Court reconsider its prior decision affirming the invalidity of Biogen's U.S. Patent No. 8,399,514, covering Tecfidera®. Following the Court's denial of Biogen's rehearing petition, the '514 patent remains invalid. Viatris' subsidiary Mylan Pharmaceuticals, Inc. launched the first therapeutically equivalent substitutable generic to Tecfidera in August 2020.

You May Also Be Interested In

• Viatris Inc (VTRS) spreader of August 17 and January 15 puts
• Diginex reports 77% revenue rise but $31M net loss in FY2026
• AS Watson signs multi-year deal with NCR Voyix for retail platform